Q2 2026 13F · SEC CIK 2088557

Defilade Capital Management, L.P.

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $746.9M
Reported positions: 39
Holdings vs S&P 500, 3 yrs: —
Assets under management: $1.5B

Defilade Capital Management, L.P. is a hedge fund that reported 39 positions worth $746.9M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Eli Lilly & Co (LLY, 6.3%), Pfizer Inc (PFE, 5.7%), Veeva Sys Inc (VEEV, 5.6%).

Defilade Capital Management, L.P. holdings all 39 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Defilade Capital Management, L.P. 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
LLYEli Lilly & Co	6.3%	2.7%	39,086	+88.9%	$46.9M
PFEPfizer Inc	5.7%	5.8%	1,771,743	+21.0%	$42.7M
VEEVVeeva Sys Inc	5.6%	New	236,709	—	$42.0M
BMRNBiomarin Pharmaceutical Inc	5.2%	New	682,005	—	$39.0M
PTCTPtc Therapeutics Inc	4.7%	3.6%	433,699	+15.3%	$35.4M
BAXBaxter Intl Inc	4.2%	New	1,459,380	—	$31.1M
INSMInsmed Inc	4.0%	4.5%	281,838	+44.6%	$30.0M
ZBHZimmer Biomet Holdings Inc	3.7%	7.4%	317,426	-45.2%	$27.3M
PODDInsulet Corp	3.6%	New	176,932	—	$26.9M
TMOThermo Fisher Scientific Inc	3.5%	New	51,934	—	$26.0M
ABTAbbott Laboratories	3.5%	New	285,778	—	$25.9M
ASNDAscendis Pharma A/s	3.4%	New	94,843	—	$25.3M
SOLVSolventum Corporation Common S	3.3%	New	316,454	—	$24.4M
MDTMedtronic PLC	3.2%	New	303,301	—	$23.7M
ELANElanco Animal Health Inc	2.8%	3.1%	864,080	-7.2%	$21.3M
AGIOAgios Pharmaceuticals Inc	2.7%	New	546,848	—	$20.3M
NVSTEnvista Holdings Corporation	2.6%	New	726,108	—	$19.1M
RVMDRevolution Medicines Inc	2.1%	4.3%	82,827	-73.8%	$15.5M
ICUIIcu Med Inc	2.1%	4.6%	105,700	-58.4%	$15.5M
COGTCogent Biosciences Inc	2.0%	1.9%	393,441	+11.6%	$15.2M
LNTHLantheus Hldgs Inc	2.0%	2.7%	132,662	-46.8%	$14.7M
OCULOcular Therapeutix Inc	2.0%	1.8%	1,490,286	+0.2%	$14.6M
ELDNEledon Pharmaceuticals Inc	1.9%	1.5%	3,525,338	-1.1%	$13.9M
TYRATyra Biosciences Inc	1.6%	New	376,870	—	$12.0M
OLMAOlema Pharmaceuticals Inc	1.5%	3.1%	924,758	-38.5%	$11.6M
ORICOric Pharmaceuticals Inc	1.5%	1.5%	1,047,690	+24.3%	$11.3M
LRMRLarimar Therapeutics Inc	1.5%	New	3,670,135	—	$11.2M
GMEDGlobus Med Inc	1.5%	4.3%	139,637	-60.6%	$11.0M
ENOVEnovis Corporation	1.5%	New	531,945	—	$11.0M
EVMNEvommune Inc	1.4%	2.2%	793,145	+16.9%	$10.5M
TFXTeleflex Incorporated	1.4%	New	80,118	—	$10.2M
DNLIDenali Therapeutics Inc Com	1.3%	3.7%	391,866	-71.2%	$10.1M
GKOSGlaukos Corp	1.2%	New	66,519	—	$9.3M
STAAStaar Surgical Co	1.2%	New	322,126	—	$9.2M
PACSPacs Group Inc	1.2%	2.7%	215,675	-64.3%	$9.2M
CRNXCrinetics Pharmaceuticals in	1.2%	New	239,440	—	$9.0M
LIVNLivanova PLC	1.2%	New	107,373	—	$8.8M
BDTXBlack Diamond Therapeutics, Inc.	0.4%	New	1,674,999	—	$3.1M
MREOMereo Biopharma Group PLC	0.3%	0.3%	7,558,756	+0.0%	$2.4M

What Defilade Capital Management, L.P. bought and sold in Q2 2026, against Q1 2026.

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: —
3 years: —
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$746.9M	39
Q1 2026	$712.2M	31
Q4 2025	$737.7M	33

Questions about Defilade Capital Management, L.P.'s portfolio

What stocks does Defilade Capital Management, L.P. own?

Defilade Capital Management, L.P.'s latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 39 positions worth $746.9M. The largest are Eli Lilly & Co (LLY) at 6.3%, Pfizer Inc (PFE) at 5.7%, Veeva Sys Inc (VEEV) at 5.6%, Biomarin Pharmaceutical Inc (BMRN) at 5.2% and Ptc Therapeutics Inc (PTCT) at 4.7%.

What did Defilade Capital Management, L.P. buy last quarter?

In Q2 2026, Defilade Capital Management, L.P. added a new position in Veeva Sys Inc (VEEV), a new position in Biomarin Pharmaceutical Inc (BMRN), a new position in Baxter Intl Inc (BAX), a new position in Insulet Corp (PODD), a new position in Thermo Fisher Scientific Inc (TMO), Eli Lilly & Co (LLY) (+88.9% shares), Insmed Inc (INSM) (+44.6% shares) and Oric Pharmaceuticals Inc (ORIC) (+24.3% shares), compared with its Q1 2026 filing.

What did Defilade Capital Management, L.P. sell last quarter?

In Q2 2026, Defilade Capital Management, L.P. sold all of Schein Henry Inc Com (HSIC), sold all of Becton Dickinson & Co (BDX), sold all of Dexcom Inc (DXCM), sold all of Intuitive Surgical Inc (ISRG), sold all of Neurocrine Biosciences Inc (NBIX), Revolution Medicines Inc (RVMD) (-73.8% shares), Denali Therapeutics Inc Com (DNLI) (-71.2% shares) and Pacs Group Inc (PACS) (-64.3% shares), compared with its Q1 2026 filing.

When is Defilade Capital Management, L.P.'s next 13F filing due?

13F filings are due 45 days after each quarter ends. Defilade Capital Management, L.P.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Defilade Capital Management, L.P. manage?

Defilade Capital Management, L.P. reported $1.5B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $746.9M.